Results 201 to 210 of about 23,672 (222)

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

Lancet Diabetes and Endocrinology,the, 2014
Mônica R Gadelha, Marcello D Bronstein, Thierry Brue   +2 more
exaly  

A Pituitary Society update to acromegaly management guidelines

Pituitary, 2020
Maria Fleseriu, Beverly M K Biller, Pamela U Freda   +2 more
exaly  

New therapeutic agents for acromegaly

Nature Reviews Endocrinology, 2015
Shlomo Melmed
exaly  

A Consensus on Criteria for Cure of Acromegaly

Journal of Clinical Endocrinology and Metabolism, 2010
Andrea Giustina, Philippe Chanson
exaly  

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

Lancet, The, 2001
Peter J Trainer, Ariel L Barkan, Laurence Katznelson   +2 more
exaly  

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

Journal of Clinical Endocrinology and Metabolism, 2014
Annamaria Colao, Maria Fleseriu
exaly  

Epidemiology of acromegaly: review of population studies

Pituitary, 2016
Niki Karavitaki
exaly  

Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities

Pituitary, 2017
Rosario Pivonello, Claudia Pivonello, Chiara Simeoli   +2 more
exaly  

Acromegaly: clinical features at diagnosis

Pituitary, 2016
Lucio Vilar
exaly  

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

Lancet, The, 2005
Aj Van Der Lely
exaly